Evolus delivered Q2 2026 revenue growth of 21% and posted positive adjusted EBITDA for the third consecutive quarter, a milestone that signals the company has moved past the cash-burn phase and into sustainable profitability. The earnings beat also prompted management to raise full-year 2026 guidance, a rare move that reflects confidence in Jeuveau's market penetration and the company's ability to manage unit economics.
Business & M&A
Evolus Posts Third Straight Profitable Quarter
Q2 revenue up 21%; adjusted EBITDA positive for third consecutive quarter; 2026 outlook raised.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Third consecutive quarter of positive adjusted EBITDA signals Evolus has moved past cash burn into sustainable profitability.
For practice owners, Evolus's trajectory matters: the company's Evolus Rewards loyalty program and direct-to-practice pricing model have been competitive levers against Allergan's dominant Allē ecosystem. Sustained profitability suggests Evolus can maintain rebate and support spending without the margin compression that often follows a pivot to breakeven. The stock's 1-year high reflects investor appetite for a pure-play aesthetics injectable company with a clear path to sustained earnings.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.